SCM
ENGN icon

Soleus Capital Management’s enGene Therapeutics ENGN Stock Holding History

Soleus Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-800,000
Closed -$5.28M – 92
2024
Q3 		$5.28M Hold
800,000
– – 0.41% 59
2024
Q2 		$7.54M Hold
800,000
– – 0.67% 47
2024
Q1 		$13.6M Buy
+800,000
New +$9.79M 1.01% 33

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Soleus Capital Management's ENGN Position: Q4 2024 in Review

Soleus Capital Management sold out of enGene Therapeutics (ENGN) in Q4 2024, closing a stake of 800,000 shares — an estimated $5.28M sold.

Soleus Capital Management first reported a position in ENGN in Q1 2024 and held it in 3 quarters. The position peaked at $13.6M in Q1 2024. 34 funds tracked by Wall St. Rank hold ENGN as of Q4 2024.

  • Soleus Capital Management reported no remaining enGene Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Soleus Capital Management sold 800,000 enGene Therapeutics shares in Q4 2024, an estimated $5.28M.
  • Soleus Capital Management first reported a position in enGene Therapeutics in Q1 2024 and held it in 3 quarters.
  • Soleus Capital Management's enGene Therapeutics position peaked at $13.6M in Q1 2024.
  • 34 funds tracked by Wall St. Rank held enGene Therapeutics as of Q4 2024.

Based on Soleus Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.